Nurulimab
Based on 1 Customer Validation
Nurulimab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) human monoclonal antibody. Nurulimab binds to CTLA-4 and blocks its interaction with ligands, stimulating T-cell proliferation, cytokine production, and inducing an antitumor immune response. Nurulimab can be used for the research of unresectable or metastatic melanoma and advanced cutaneous melanoma.
For research use only. We do not sell to patients.
- Purity : 95.00%
- CAS No.: 2168561-20-2
- Molecular Weight:143.78 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
CTLA4
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Research Protocol for Inflammation-related Diseases
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- MTT Cell Proliferation Assay
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Nurulimab (anti-CTLA4) (HY-P99760). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Product Details
-
CAS No. 2168561-20-2
-
Accession P16410
-
Synonyms BCD-145
-
Molecular Weight 143.78 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
95.00%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Nurulimab
- 2168561-20-2
- BCD-145
- BCD145
- BCD 145
- CTLA-4
- Cytotoxic T-lymphocyte-associated protein 4
- CD152
- cytotoxic T-lymphocyte-associated antigen 4
- T-cell
- HLA-DR+ CD4+ T lymphocytes
- CD4+ICOS+ T-lymphocytes
- metastatic melanoma
- cytokine
- CD8+ T lymphocytes
- antitumor immune response
- unresectable melanoma
- Inhibitor
- inhibitor
- inhibit